Markets:

Overview

News

Currencies

International

Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

5.395 +0.035 (+0.65%)

Streaming Delayed Price Updated: 10:47 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Get insights into the top gainers and losers of Friday's pre-market session. ↗

October 24, 2025

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 24, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 23, 2025

Via Benzinga

EXCLUSIVE: Coya Therapeutics Investigational Combination Therapy With GLP-1 Shows Potential For Alzheimer's Disease ↗

September 16, 2025

Coya's COYA 303 showed strong immune modulation and reduced inflammation in the brain, supporting its development for neurodegenerative diseases like Alzheimer's.

Via Benzinga

COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023 ↗

March 19, 2024

Coya Therapeutics just reported results for the fourth quarter of 2023.

Via InvestorPlace

Coya Therapeutics ↗

February 29, 2024

100% technical buy signals. 15 new highs and up 43.21% in the last month. 74.87+ Weighted Alpha

Via Talk Markets

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 25, 2025

Via Benzinga

What's Going On With Coya Therapeutics Stock? ↗

August 25, 2025

Shares of Coya Therapeutics are trading higher Monday morning. The company provided an update regarding the development of a new treatment for Amyotrophic Lateral Sclerosis.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 25, 2025

Via Benzinga

Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗

May 01, 2025

Via Benzinga

Analyst Expectations for Coya Therapeutics's Future ↗

July 17, 2023

Via Benzinga

The Latest Analyst Ratings for Coya Therapeutics ↗

June 08, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 03, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

March 14, 2025

Via Benzinga

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing ↗

February 06, 2025

Coya Therapeutics' Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer's patients, with no serious adverse events.

Via Benzinga

EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases ↗

January 21, 2025

Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect.

Via Benzinga

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study ↗

October 29, 2024

Coya Therapeutics reports mixed data from Phase 2 study of low-dose IL-2 in Alzheimer's, showing safety and potential cognitive benefits in q4wks regimen.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 29, 2024

Via Benzinga

This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗

September 16, 2024

Via Benzinga

COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024 ↗

August 12, 2024

COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

7 Biotech Stocks to Put on Your Breakthrough Radar ↗

May 27, 2024

Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.

Via InvestorPlace

EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases ↗

May 27, 2024

Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD,...

Via Benzinga

COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024 ↗

May 09, 2024

COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases ↗

February 05, 2024

Dr. Howard Burman, Ph.D, CEO and Dr. Arun Swaminathan, CBO, of Coya Therapeutics Inc (NASDAQ: COYA), were guests on Benzinga’s All Access.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 01, 2023

Via Benzinga

How The Same Treatments May Work For Multiple Neurodegenerative Diseases ↗

September 21, 2023

Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.

Via Talk Markets

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 07, 2023

Via Benzinga

Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation ↗

July 17, 2023

Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients

Via Benzinga

The Immunotherapy Market Is Expected To Surpass $351.56 Billion By 2030 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) Is Contributing to This Growth ↗

July 12, 2023

Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this...

Via Benzinga

Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗

June 08, 2023

Raymond James cut the price target for Brinker International, Inc. (NYSE: EAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.